Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects

NCT02508168 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02508168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02508168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2016
Completion date
April 30, 2016
Enrollment
24 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers